GlassScriptPhysician profile
Lawrence Delmore Bailey
NPI 1437134723
$5,365.54
in general payments reported to CMS, 2019-2025
33 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $599 · 2021: $745 · 2022: $789 · 2023: $842 · 2024: $816 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,781.62 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $674.18 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.60 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $451.67 | 2019-2025 | |
| Pfizer INC. | $246.89 | 2019-2025 | |
| Janssen Biotech, INC. | $201.80 | 2020-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $179.43 | 2019-2025 | Ocaliva |
| Celgene Corporation | $173.04 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $154.27 | 2022-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $108.06 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $70.06 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $67.94 | 2021-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $67.07 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $63.84 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $60.64 | 2025 | Rezdiffra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $50.10 | 2020-2025 | Injectafer |
| Conmed Corporation | $49.46 | 2022 | |
| Nestle Healthcare Nutrition INC. | $48.95 | 2021-2022 | |
| Novo Nordisk INC | $40.17 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $38.72 | 2023 | Dificid |
| Braintree Laboratories, INC. | $35.28 | 2019-2024 | Suflave, Sutab |
| Allergan, INC. | $34.50 | 2020 | |
| Romark Laboratories, Lc | $32.51 | 2020 | |
| Ironwood Pharmaceuticals, INC | $27.26 | 2019-2022 | |
| Genzyme Corporation | $27.19 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $24.73 | 2025 | Voquezna |
| Mirum Pharmaceuticals, INC. | $20.67 | 2025 | Livmarli |
| Evoke Pharma, INC. | $19.17 | 2024 | |
| Olympus America INC. | $18.57 | 2025 | Olympus, Ezdilate, Olympus |
| Redhill Biopharma INC. | $16.95 | 2022 | |
| Sandoz INC. | $16.86 | 2024 | Hyrimoz |
| Intra-Sana Laboratories | $14.47 | 2022 | |
| Shionogi INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.